Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Antonia L. Pritchard is active.

Publication


Featured researches published by Antonia L. Pritchard.


Cortex | 2007

Cognitive Phenotypes in Alzheimer's Disease and Genetic Risk

Julie S. Snowden; Cheryl L. Stopford; Camille L. Julien; Jennifer C. Thompson; Yvonne S. Davidson; Linda Gibbons; Antonia L. Pritchard; Corinne Lendon; Anna Richardson; Anoop Varma; David Neary; David Mann

Variation in the clinical characteristics of patients with Alzheimers disease (AD) is increasingly recognised, although the factors underlying variation are not fully understood. The study examined the cognitive characteristics of 523 AD patients at the time of their presentation to a neurological dementia clinic and explored the relationship to family history and apolipoprotein E (APOE) genotype. Distinct profiles were identified, which were mirrored by topographical differences on neuroimaging. Clinical distinctions were maintained over time. Two-thirds of patients showed a constellation of deficits at presentation which included memory, language, visuospatial and constructional difficulties. However, a quarter had circumscribed presentations of amnesia, aphasia, perceptuospatial disorder or apraxia. The rare presence of frontal lobe characteristics was associated with a younger age of onset, an increased incidence of myoclonus at presentation, a positive family history but not with possession of APOE epsilon4 allele. An amnestic presentation (severe, yet circumscribed amnesia) was strongly associated with an older age of onset, a positive family history and the presence of APOE epsilon4 allele. Posterior cortical presentations showed a female bias, were typically sporadic, and showed no association with APOE epsilon4. The findings support the notion of phenotypic variation in AD, and show that genetic risk factors can influence clinical presentation. The findings draw attention to the specific association between APOE epsilon4 allele and memory but challenge the commonly held notion that the presence of the epsilon4 allele inevitably reduces onset age. The findings indicate that risk factors other than APOE epsilon4 allele underlie the non-familial, early onset posterior hemisphere presentations of AD.


Nature Genetics | 2014

POT1 loss-of-function variants predispose to familial melanoma

Carla Daniela Robles-Espinoza; Mark Harland; Andrew J. Ramsay; Lauren G. Aoude; Zhihao Ding; Karen A. Pooley; Antonia L. Pritchard; Jessamy Tiffen; Mia Petljak; Jane M. Palmer; Judith Symmons; Peter Johansson; Mitchell S. Stark; Michael Gartside; Helen Snowden; Grant W. Montgomery; Nicholas G. Martin; Jimmy Z. Liu; Jiyeon Choi; Matthew Makowski; Kevin M. Brown; Alison M. Dunning; Thomas M. Keane; Carlos López-Otín; Nelleke A. Gruis; Nicholas K. Hayward; D. Timothy Bishop; Julia Newton-Bishop; David J. Adams

Deleterious germline variants in CDKN2A account for around 40% of familial melanoma cases, and rare variants in CDK4, BRCA2, BAP1 and the promoter of TERT have also been linked to the disease. Here we set out to identify new high-penetrance susceptibility genes by sequencing 184 melanoma cases from 105 pedigrees recruited in the UK, The Netherlands and Australia that were negative for variants in known predisposition genes. We identified families where melanoma cosegregates with loss-of-function variants in the protection of telomeres 1 gene (POT1), with a proportion of family members presenting with an early age of onset and multiple primary tumors. We show that these variants either affect POT1 mRNA splicing or alter key residues in the highly conserved oligonucleotide/oligosaccharide-binding (OB) domains of POT1, disrupting protein-telomere binding and leading to increased telomere length. These findings suggest that POT1 variants predispose to melanoma formation via a direct effect on telomeres.


Nature | 2017

Whole-genome landscapes of major melanoma subtypes

Nicholas K. Hayward; James S. Wilmott; Nicola Waddell; Peter A. Johansson; Matthew A. Field; Katia Nones; Ann Marie Patch; Hojabr Kakavand; Ludmil B. Alexandrov; Hazel Burke; Valerie Jakrot; Stephen Kazakoff; Oliver Holmes; Conrad Leonard; Radhakrishnan Sabarinathan; Loris Mularoni; Scott Wood; Qinying Xu; Nick Waddell; Varsha Tembe; Gulietta M. Pupo; Ricardo De Paoli-Iseppi; Ricardo E. Vilain; Ping Shang; Loretta Lau; Rebecca A. Dagg; Sarah-Jane Schramm; Antonia L. Pritchard; Ken Dutton-Regester; Felicity Newell

Melanoma of the skin is a common cancer only in Europeans, whereas it arises in internal body surfaces (mucosal sites) and on the hands and feet (acral sites) in people throughout the world. Here we report analysis of whole-genome sequences from cutaneous, acral and mucosal subtypes of melanoma. The heavily mutated landscape of coding and non-coding mutations in cutaneous melanoma resolved novel signatures of mutagenesis attributable to ultraviolet radiation. However, acral and mucosal melanomas were dominated by structural changes and mutation signatures of unknown aetiology, not previously identified in melanoma. The number of genes affected by recurrent mutations disrupting non-coding sequences was similar to that affected by recurrent mutations to coding sequences. Significantly mutated genes included BRAF, CDKN2A, NRAS and TP53 in cutaneous melanoma, BRAF, NRAS and NF1 in acral melanoma and SF3B1 in mucosal melanoma. Mutations affecting the TERT promoter were the most frequent of all; however, neither they nor ATRX mutations, which correlate with alternative telomere lengthening, were associated with greater telomere length. Most melanomas had potentially actionable mutations, most in components of the mitogen-activated protein kinase and phosphoinositol kinase pathways. The whole-genome mutation landscape of melanoma reveals diverse carcinogenic processes across its subtypes, some unrelated to sun exposure, and extends potential involvement of the non-coding genome in its pathogenesis.


Dementia and Geriatric Cognitive Disorders | 2007

Role of Serotonin Transporter Polymorphisms in the Behavioural and Psychological Symptoms in Probable Alzheimer Disease Patients

Antonia L. Pritchard; Colin W. Pritchard; Peter Bentham; Corinne Lendon

Background/Aims: Alzheimer disease (AD) patients commonly suffer from behavioural and psychological symptoms of dementia (BPSD). A genetic component to BPSD development in AD has been demonstrated. This is an investigation of whether the linked polymorphic region and variable number tandem repeat variants of the serotonin transporter (SERT) are associated with BPSD. Methods: The longitudinal measures of BPSD of our large cohort of 367 AD patients were assessed by the Neuropsychiatric Inventory. Measures with good evidence of serotonergic involvement (delusions, hallucinations, depression, anxiety, agitation/aggression and irritability) were related to genotype and allele frequencies of the linked polymorphic region and variable number tandem repeat variants. Results: Analysis revealed significant relationships between the linked polymorphic region variant long allele with irritability and the variable number tandem repeat 10-repeat allele with psychosis, but no associations were found with depression, anxiety or agitation/aggression. Conclusion: Our data and review of previous studies suggest SERT could play a minor role in development of psychosis and aggressive/irritable tendencies; however, further investigations are required in large, well-characterized cohorts.


Neurobiology of Aging | 2008

Role of 5HT2A and 5HT2C polymorphisms in behavioural and psychological symptoms of Alzheimer's disease

Antonia L. Pritchard; Judith Harris; Colin W. Pritchard; John Coates; Sayeed Haque; Roger Holder; Peter Bentham; Corinne Lendon

Abstract Objective Alzheimers disease (AD) patients suffer from behavioural and psychological symptoms of dementia (BPSD). A genetic component to BPSD development in AD has been demonstrated. Polymorphisms within serotonin receptors 5HT2A and 5HT2C have been previously investigated in a few interesting studies reviewed here, however, their role remains unclear. Methods Our large cohort of 394 patients had longitudinal information on the BPSD (Neuropsychiatric Inventory), which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period and give each patient a severity score. These measures were related to the 5HT2A T102C and 5HT2C cys23ser genotype and allele frequencies. Results Our data supports previous reports of an increased frequency of the C allele and CC genotype of the T102C variant of 5HT2A with hallucinations, delusions, psychosis and aberrant motor behaviour, however, we dispute previous associations with depression and aggression. We describe for the first time an increase in the C allele and CC genotype frequencies of the cys23ser variant of 5HT2C with anxiety and support previous associations with appetite disturbances in females. Conclusion This review and extension of previous data presents support for the role of 5HT2A and 5HT2C in the development of certain symptoms, although the effect size may be small.


Journal of Immunology | 2012

Innate IFNs and Plasmacytoid Dendritic Cells Constrain Th2 Cytokine Responses to Rhinovirus: A Regulatory Mechanism with Relevance to Asthma

Antonia L. Pritchard; Melanie L. Carroll; Julie G. Burel; Olivia J. White; Simon Phipps; John W. Upham

Human rhinoviruses (RV) cause only minor illness in healthy individuals, but can have deleterious consequences in people with asthma. This study sought to examine normal homeostatic mechanisms regulating adaptive immunity to RV in healthy humans, focusing on effects of IFN-αβ and plasmacytoid dendritic cells (pDC) on Th2 immune responses. PBMC were isolated from 27 healthy individuals and cultured with RV16 for up to 5 d. In some experiments, IFN-αβ was neutralized using a decoy receptor that blocks IFN signaling, whereas specific dendritic cell subsets were depleted from cultures with immune-magnetic beads. RV16 induced robust expression of IFN-α, IFN-β, multiple IFN-stimulated genes, and T cell-polarizing factors within the first 24 h. At 5 d, the production of memory T cell-derived IFN-γ, IL-10, and IL-13, but not IL-17A, was significantly elevated. Neutralizing the effects of type-I IFN with the decoy receptor B18R led to a significant increase in IL-13 synthesis, but had no effect on IFN-γ synthesis. Depletion of pDC from RV-stimulated cultures markedly inhibited IFN-α secretion, and led to a significant increase in expression and production of the Th2 cytokines IL-5 (p = 0.02), IL-9 (p < 0.01), and IL-13 (p < 0.01), but had no effect on IFN-γ synthesis. Depletion of CD1c+ dendritic cells did not alter cytokine synthesis. In healthy humans, pDC and the IFN-αβ they secrete selectively constrain Th2 cytokine synthesis following RV exposure in vitro. This important regulatory mechanism may be lost in asthma; deficient IFN-αβ synthesis and/or pDC dysfunction have the potential to contribute to asthma exacerbations during RV infections.


Clinical Genetics | 2015

A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma

Karin Wadt; Lauren G. Aoude; Peter A. Johansson; Annalisa Solinas; Antonia L. Pritchard; Oana Crainic; M. T. Andersen; Jens Folke Kiilgaard; Steffen Heegaard; Lone Sunde; B. Federspiel; Jason Madore; John F. Thompson; Stanley W. McCarthy; A. Goodwin; Hensin Tsao; Göran Jönsson; Ruta Gupta; Jeffrey M. Trent; Anne-Marie Gerdes; Kevin M. Brown; Richard A. Scolyer; Nicholas K. Hayward

We report four previously undescribed families with germline BRCA1‐associated protein‐1 gene (BAP1) mutations and expand the clinical phenotype of this tumor syndrome. The tumor spectrum in these families is predominantly uveal malignant melanoma (UMM), cutaneous malignant melanoma (CMM) and mesothelioma, as previously reported for germline BAP1 mutations. However, mutation carriers from three new families, and one previously reported family, developed basal cell carcinoma (BCC), thus suggesting inclusion of BCC in the phenotypic spectrum of the BAP1 tumor syndrome. This notion is supported by the finding of loss of BAP1 protein expression by immunochemistry in two BCCs from individuals with germline BAP1 mutations and no loss of BAP1 staining in 53 of sporadic BCCs consistent with somatic mutations and loss of heterozygosity of the gene in the BCCs occurring in mutation carriers. Lastly, we identify the first reported recurrent mutation in BAP1 (p.R60X), which occurred in three families from two different continents. In two of the families, the mutation was inherited from a common founder but it arose independently in the third family.


Journal of Neurology, Neurosurgery, and Psychiatry | 2007

The effect of the apolipoprotein E gene polymorphisms and haplotypes on behavioural and psychological symptoms in probable Alzheimer’s disease

Antonia L. Pritchard; Judith Harris; Colin W. Pritchard; John Coates; Sayeed Haque; Roger Holder; Peter Bentham; Corinne Lendon

Background: Patients with Alzheimer’s disease and dementia commonly suffer from behavioural and psychological symptoms of dementia (BPSD). A genetic component to BPSD development in Alzheimer’s disease has been demonstrated. Several studies have investigated whether the exon 4 ε2/ε3/ε4 haplotype of the apolipoprotein E (APOE) gene is associated with BPSD, with variable results. Objective: We investigated the exon 4 polymorphisms and extended this study to include promoter polymorphisms and the resultant haplotypes across the gene. Methods: Our large independent cohort of 388 patients with longitudinal measures of BPSD assessed by the Neuropsychiatric Inventory was used to analyse whether any of these variants were associated with the presence of BPSD. Results: We revealed several significant relationships before correction for multiple testing. The exon 4 haplotype was associated with hallucinations and anxiety, A-491T with irritability, T-427C with agitation/aggression and appetite disturbances, and T-219C with depression. Haplotype analyses of all variants did not reveal any statistically significant findings. Conclusions: Our data and a review of previous studies showed a diversity of relationships, suggesting that these findings might be due to chance and so collectively do not support a role for the APOE gene in BPSD.


Neurology | 2003

Genetic variation of the APOE promoter and outcome after head injury.

Corinne Lendon; Judith Harris; Antonia L. Pritchard; James A. R. Nicoll; G. M. Teasdale; Gordon Murray

The APOE-ε4 allele is associated with risk for Alzheimer’s disease (AD) and poorer outcome after head injury. Several studies show that polymorphisms in the promoter that influence APOE expression also increase risk for AD. The authors’ data from a study of 92 patients are consistent with a possible influence of the G-219T promoter polymorphism on outcome after head injury. The group with unfavorable outcome had a genotype frequency distribution similar to that found in AD.


Pigment Cell & Melanoma Research | 2015

Genetics of familial melanoma: 20 years after CDKN2A

Lauren G. Aoude; Karin Wadt; Antonia L. Pritchard; Nicholas K. Hayward

Twenty years ago, the first familial melanoma susceptibility gene, CDKN2A, was identified. Two years later, another high‐penetrance gene, CDK4, was found to be responsible for melanoma development in some families. Progress in identifying new familial melanoma genes was subsequently slow; however, with the advent of next‐generation sequencing, a small number of new high‐penetrance genes have recently been uncovered. This approach has identified the lineage‐specific oncogene MITF as a susceptibility gene both in melanoma families and in the general population, as well as the discovery of telomere maintenance as a key pathway underlying melanoma predisposition. Given these rapid recent advances, this approach seems likely to continue to pay dividends. Here, we review the currently known familial melanoma genes, providing evidence that most additionally confer risk to other cancers, indicating that they are likely general tumour suppressor genes or oncogenes, which has significant implications for surveillance and screening.

Collaboration


Dive into the Antonia L. Pritchard's collaboration.

Top Co-Authors

Avatar

Corinne Lendon

QIMR Berghofer Medical Research Institute

View shared research outputs
Top Co-Authors

Avatar

Nicholas K. Hayward

QIMR Berghofer Medical Research Institute

View shared research outputs
Top Co-Authors

Avatar

John W. Upham

University of Queensland

View shared research outputs
Top Co-Authors

Avatar

Julie G. Burel

University of Queensland

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Peter Bentham

University of Birmingham

View shared research outputs
Top Co-Authors

Avatar

Ken Dutton-Regester

QIMR Berghofer Medical Research Institute

View shared research outputs
Top Co-Authors

Avatar

Lauren G. Aoude

QIMR Berghofer Medical Research Institute

View shared research outputs
Top Co-Authors

Avatar

Peter A. Johansson

QIMR Berghofer Medical Research Institute

View shared research outputs
Top Co-Authors

Avatar

Judith Harris

University of Birmingham

View shared research outputs
Researchain Logo
Decentralizing Knowledge